Last Updated: August 8, 2026

Litigation Details for TRUSTID, Inc. v. Next Caller Inc. (D. Del. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in TRUSTID, Inc. v. Next Caller Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Patent/Commercial Impact Analysis: TRUSTID, Inc. v. Next Caller Inc. (1:18-cv-00172)

Last updated: July 6, 2026

TrustID, Inc. sued Next Caller Inc. in the U.S. District Court under case number 1:18-cv-00172. The publicly accessible docket content required to provide a litigation summary with claim-level substance, asserted causes of action, venue-specific procedural posture, deadlines, and outcomes is not present in the information available here.

No complete, accurate litigation narrative (including asserted patents/trade secrets, infringement theories, claim construction activity, dispositive motion rulings, settlement terms, or dismissal/judgment specifics) can be produced from the provided input alone.

What is the lawsuit status for TRUSTID, Inc. v. Next Caller Inc. (1:18-cv-00172)?

Answer: Status, procedural posture, and final disposition are not determinable from the provided information.

Which court handled TRUSTID v. Next Caller and what was the procedural posture?

Answer: Court division, judge, and key procedural steps (complaint filing date, service, motions to dismiss, answer, discovery, claim construction, summary judgment, trial, or dismissal) are not determinable from the provided information.

Was there a settlement, dismissal, or final judgment?

Answer: Settlement or outcome cannot be stated from the provided information.

What claims were asserted in TRUSTID, Inc. v. Next Caller Inc. (1:18-cv-00172)?

Answer: The asserted causes of action and the underlying intellectual property theory (patent infringement, trade secret misappropriation, copyright, trademark, contract, CFAA, etc.) are not determinable from the provided information.

Which patents or IP rights were at issue?

Answer: No asserted patent numbers, application publications, trade-secret lists, or right holders can be identified from the provided information.

What products or services were accused?

Answer: No accused functionality, service names, or feature mapping can be identified from the provided information.

What does the complaint allege about infringement, misappropriation, or use of protected technology?

Answer: The complaint’s technical allegations cannot be summarized because the complaint’s substantive content is not provided.

How did TRUSTID frame liability (direct, indirect, contributory)?

Answer: Not determinable from the provided information.

Did TRUSTID assert method claims, system claims, or specific functional modules?

Answer: Not determinable from the provided information.

How does the litigation affect TRUSTID’s enforceability strategy and Next Caller’s risk profile?

Answer: Without the asserted rights and procedural outcome, enforceability and risk cannot be analyzed in an evidence-based way.

What is the impact on Next Caller’s product roadmap or licensing exposure?

Answer: Not determinable from the provided information.

What is the impact on other competitors using similar anti-fraud, caller-ID, or identity verification mechanisms?

Answer: Not determinable from the provided information.

What patent expiration timelines, exclusivity, and licensing leverage matter for this case?

Answer: Patent expiration, exclusivity, and licensing leverage cannot be assessed without the specific asserted rights.

When did the asserted patents file and expire?

Answer: Not determinable from the provided information.

Were there settlement-linked license agreements or consent decrees?

Answer: Not determinable from the provided information.

What procedural events, motion practice, and rulings shaped the case?

Answer: Key procedural events and rulings are not determinable from the provided information.

Were there motions to dismiss under Rule 12(b), stay motions, or jurisdiction challenges?

Answer: Not determinable from the provided information.

Were claim construction or summary judgment motions decided?

Answer: Not determinable from the provided information.

What does the case docket indicate about timelines and discovery scope?

Answer: Docket milestones required to quantify timelines are not available in the provided information.

When did discovery open and what issues were targeted?

Answer: Not determinable from the provided information.

Were expert reports exchanged and were Daubert challenges filed?

Answer: Not determinable from the provided information.

How does this case compare with other identity verification or caller-identity IP litigations?

Answer: A comparative landscape requires asserted rights, claims, and outcomes from this case and comparable cases; none are provided.

Are there similar disputes involving caller identity verification, anti-spoofing, or trust scoring?

Answer: Not determinable from the provided information.

Key Takeaways

  • The only available information is the case caption and docket number: TRUSTID, Inc. v. Next Caller Inc., 1:18-cv-00172.
  • A litigation summary that is accurate and decision-useful requires docket and pleading content that is not present here.
  • No claim-level, patent-level, or outcome-level analysis can be provided without risking factual errors.

FAQs

  1. What court division and judge handled TRUSTID, Inc. v. Next Caller Inc. (1:18-cv-00172)?
  2. What patents or IP rights did TRUSTID assert in 1:18-cv-00172?
  3. Did the court grant any injunction, TRO, or preliminary relief in 1:18-cv-00172?
  4. Was there a settlement or dismissal, and on what terms, in TRUSTID v. Next Caller?
  5. What defenses did Next Caller raise (invalidity, non-infringement, standing, preemption, jurisdiction)?

References

  1. (No citable sources provided in the input.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.